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ABSTRACT 
 
Introduction 
Vitamin D has numerous important functions in the human body. There is limited 
data available regarding vitamin D status in children with Chronic Kidney Disease 
(CKD) in South Africa. 
 
Objectives 
To determine the vitamin D status, as well as factors that affect it, in children with 
CKD in Johannesburg, South Africa. 
 
Methods 
A cross-sectional observational study was performed on 69 patients who attended 
the Renal Outpatient Clinic, and required routine phlebotomy, at Charlotte Maxeke 
Johannesburg Academic Hospital, Division of Paediatric Nephrology, between 
20/08/2013 and 20/05/2014. 
 
Results 
71% (n=49) of patients in our study sample were vitamin D sufficient. Significant 
factors that influenced vitamin D status included albumin levels and the presence 
of Nephrotic syndrome with relapse.  
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There was a statistically significant positive correlation between albumin and 
vitamin D (p=0.00). As albumin levels increased so did the vitamin D levels. 
Patients with Nephrotic Syndrome with relapse had significantly lower vitamin D 
levels compared to patients with Nephrotic Syndrome in remission (p=0.00). 
 
Conclusion 
The majority of children with Chronic Kidney Disease in Johannesburg, South 
Africa, are vitamin D sufficient. This is reassuring as it implies that there is no need 
for routine vitamin D supplementation in this sample of children. However patients, 
especially those with nephrotic syndrome with relapse, still need to be screened 
for vitamin D deficiency and insufficiency and supplemented if necessary. 
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1.0 INTRODUCTION 
 
1.1 Literature Review 
Vitamin D is produced from photosynthesis in the skin and dietary sources. 
Cholecalciferol (D3) and ergocalciferol (D2) are precursors that are hydroxylated to 
calcidiol (25-hydroxyvitamin D)(25OHD) in the liver. Calcidiol is converted to 
calcitriol (1-25-dihydroxyvitamin D), an active form of vitamin D, by the enzyme 1-
alpha-hydroxylase, in the kidney. Calcitriol binds to vitamin D receptors that are 
found in many tissues in the body. Some of the major functions of vitamin D 
include calcium homeostasis, immune regulation and regulation of cell growth. 1 
 
Renal production of 1-25-dihydroxyvitamin D is tightly regulated by plasma 
parathyroid hormone levels and serum calcium and phosphate levels. Low 
extracellular calcium stimulates the parathyroid glands to secrete parathyroid 
hormone (PTH). An increase in PTH up-regulates 1-alpha-hydroxylase resulting in 
an increase in the synthesis of 1-25-dihydroxyvitamin D. 2 
 
Vitamin D binding protein (VDBP) plays an important role in renal vitamin D 
metabolism by transporting vitamin D metabolites in the blood. 80-90% of 25OHD 
and 1-25-dihydroxyvitamin D circulate bound to VDBP, 10-15% is bound to 
albumin and <1% is in their free form. In CKD, changes in the concentration of 
VDBP due to glomerular and/or tubular damage could impair vitamin D transport 
and metabolism. This may influence the bioavailability of 25OHD to target  
tissues. 5 
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Predisposing factors for vitamin D deficiency include reduced skin synthesis as a 
result of sunscreen use or reduced exposure to sunlight among the housebound. 
Other factors include reduced bioavailability as a result of malabsorption or 
obesity, increased catabolism from drugs such as anticonvulsants, increased 
urinary loss in nephrotic syndrome and impaired vitamin D hydroxylation or 
activation. 3  
 
There is a high prevalence of vitamin D deficiency in children with Chronic Kidney 
Disease (CKD). They are more likely to have lower 25OHD levels due to reduced 
exposure to sunlight, a reduced intake of foods that contain vitamin D4 as well as a 
reduced production of circulating 1-25-dihydroxyvitamin D by the kidney 5.  
Lower levels of 25 hydroxy vitamin D (25OHD) are found in children with Nephrotic 
Syndrome, a specific kidney disease in childhood, especially during a relapse, due 
to the loss of 25OHD and vitamin D binding protein6. This has been found in 
numerous studies done previously on this topic4, 7. In addition, lower levels of 
25OHD have also been found in patients on haemodialysis and on peritoneal  
dialysis 6,11,12. 
 
There is limited data available regarding the vitamin D status in children with CKD 
in South Africa. In a review published in the Indian Journal of Paediatrics, vitamin 
D deficiency was highly prevalent in children with Chronic Kidney Disease8. 
Included in the review was a study by Menon et al. where 56.1% of patients had 
vitamin D insufficiency and 21.1% were deficient of vitamin D9. Another study by 
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Kalkwarf et al. found that nearly half of children included in the study with stage 2-
5 kidney disease were vitamin D deficient10.  
 
Similar results were found in a study based in Miami, where more than half of 
patients across all stages of CKD did not have sufficient vitamin D levels (32% had 
vitamin D insufficiency and 28% were deficient in vitamin D)11. Factors that may 
contribute to these findings include the fact that chronically ill children may not 
spend as much time outdoors thus minimizing the amount of sunlight they’re 
exposed to. Other factors that may influence vitamin D status include sex, age, 
season, and Body Mass Index (BMI) 5,13,14,15,26,27,28. 
 
A study by Denburg et al. found that the concentration of all vitamin D metabolites 
were lower with advanced CKD5. Winter season and older age were associated 
with lower concentrations of free and bioavailable 25OHD5. Black race was 
associated with lower total 25OHD, but not free or bioavailable 25OHD 5. Another 
study published in the Journal of Paediatrics also found lower mean 25OHD levels 
in winter compared to summer9. In the same study, rates of vitamin D insufficiency 
and deficiency were similar in male and female patients but significantly higher in 
older and overweight patients 11. Obesity alters the release of vitamin D into the 
circulation and decreases its bioavailability because of deposition in adipose tissue 
compartments12. 
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In a study published in the United States of America, mean total vitamin D intake 
was found to be less in the low-income group compared to the high-income 
category, although results were not significant11. In addition, whites had a 
significantly higher total intake of vitamin D than blacks and Hispanics 13. Closer to 
home, it was found that children living in the majority of developing countries were 
found to have a calcium intake one third to a half of those children living in 
developed countries14. It is important to note, however, that these studies were not 
done on children with CKD. Further studies are required to investigate the calcium 
intake and socioeconomic status with regards to vitamin D status in children with 
CKD. 
 
Our motivation for conducting this study was to look at the vitamin D status in 
children with a spectrum of renal disease in Johannesburg, South Africa, in order 
to determine if there might be a need for vitamin D supplementation in this sample 
of patients. 
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1.2 Aim 
To determine the vitamin D status in children with renal disease attending the 
Renal Outpatient Clinic at the Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), Division of Paediatric Nephrology, between 20/08/2013 and 20/05/2014. 
 
 
 
 
1.3 Objectives 
To determine the effect of the following factors on Vitamin D status:  
i) Age 
ii) Sex 
iii) Race 
iv) Financial status 
v) Season 
vi) Body Mass Index (BMI) 
vii) Estimated Glomerular Filtration Rate (eGFR) 
viii) Duration of illness 
ix) Peritoneal Dialysis 
x) Serum albumin level 
xi) Nephrotic Syndrome with relapse 
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2.0 STUDY DESIGN AND METHODS 
 
2.1 Study Design 
A cross-sectional observational study was performed on all patients who attended 
the Renal Outpatient Clinic at the Division of Paediatric Nephrology, CMJAH, 
between 20/08/2013 and 20/05/2014, and who required routine phlebotomy.  
 
Inclusion/Exclusion Criteria 
All patients described above were included in the study, namely, those who 
routinely required phlebotomy at the visit. This cohort consisted of patients with 
CKD and others with renal disease attending the clinic. Patients who did not 
require routine phlebotomy were excluded from the study because the ethics 
application specifically stated that we would not subject our patients to the pain of 
an additional needlestick for the purposes of the study. Patients were included 
provided that consent/assent was obtained. 
 
The ages ranged from 8 months to 24 years. These accounted for 90% of the total 
number of patients attending the Renal Clinic.  
 
 
2.2 Sample Size 
The minimum number (n) of children required for the study was calculated using 
the formula: 15  
n = z2 p(1-p)/d2 
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‘z’ is the standard normal deviate corresponding to the 95% confidence interval = 
1.96 
‘p’ is the estimated prevalence of vitamin D deficiency in children with renal 
disease from a previous study = 0.07 16 
‘d’ is the absolute sampling error that can be tolerated = 0.05 
Therefore, the minimum sample size is ‘n’ = 100 
 
The number of participants in our study (74) was short of the minimum 
requirement of 100. This was due to time constraints for the data collection period 
as well as a lack of funding. 
 
2.3 Study Methods 
All patients who met the criteria for inclusion in the study had an extra 
ethylenediaminetetraacetic acid (EDTA) blood tube taken for 25 hydroxy vitamin D 
(25OHD) analysis. We opted to measure 25OHD as opposed to 1-25-
dihydroxyvitamin D because we wanted to determine the vitamin D status, not how 
it is metabolized. We did not subject any child to an additional needle stick. 
 
The blood samples were taken, within 4 hours, to the Chemistry Laboratory at the 
University of the Witwatersrand (on the same property as the hospital), where they 
were spun. The spun samples were stored in a freezer at -80 degrees Celsius until 
analysis. Samples were run on a high performance liquid chromatography (HPLC) 
with photo diodo array (PDA) using a commercially available kit method for vitamin 
D analysis (RECIPE ClinRep HPLC Kit, Munich, Germany). Plasma samples were 
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extracted using liquid-liquid extraction techniques as described on the package 
insert. 50μl of supernatant was then injected onto the HPLC system for detection. 
Control checks were in place to ensure standardization of results.  
 
An HPLC photodiode detector was used for the analysis. This separated the 
25OHD into vitamin D2 and D3, which were then added together to get a total. 
Matrix matches internal controls, which are commercially available, were run on 
every 10 samples. This was at two levels, which span the analytical range of the 
assay. The assay CV was 8% at the low range and 7.4% at the high range. The 
inter-assay CV ranged from 4.1-10.8% and intra-assay CV from 0.3-9.6%. 
External quality assurance was performed using DEQAS, which was run every 
month. Internal quality controls were run on every 10 samples and extracted with 
the samples per batch prepared. 
 
All results were reported in the unit nmol/L. 
 
Vitamin D binding protein was not measured as our laboratory did not have the 
facilities to do so, and we did not have enough funding to outsource it. 
 
2.4 Biochemical Determinations and Definitions 
Vitamin D status: Vitamin D status was defined according to serum 25OHD levels, 
in accordance with Institute of Medicine guidelines17, namely;  
o Vitamin D deficient <30nmol/L 
o Vitamin D insufficient 30-50nmol/L  
o Vitamin D replete >50nmol/L  
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The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice 
guidelines were used to classify the CKD stage of our patients18. 
 
Financial Status: Patients’ families were divided into two groups namely those that 
were exempted from paying a hospital fee (“Non Paying”) and those that had to 
pay as per hospital criteria (“Paying”). 
 
Season: The seasons were divided into two groups. Group One included winter 
and spring, and Group Two included summer and autumn. 
 
BMI: BMI was calculated using the weight (kg) divided by height (m) squared. 
Anthropometric z scores were calculated using the World Health Organization 
(WHO) Anthro and AnthroPlus software programmes (Department of Nutrition, 
WHO, Geneva, Switzerland). 
 
Glomerular Filtration Rate: GFR was estimated from the patient’s height and 
creatinine using the modified Schwartz formula19.  
 
Duration of illness: This was defined as the interval between the date of the first 
presentation of the patient to the clinic and the date of phlebotomy. 
 
Nephrotic Syndrome relapse: Patients were defined as having Nephrotic 
Syndrome relapse if they were known to have a diagnosis of Nephrotic Syndrome 
and had, on urine dipstix performed up to six months prior to the blood sample 
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being taken, greater than or equal to 2+ proteinuria detected. This was an arbitrary 
definition recommended by the Division of Paediatric Nephrology at CMJAH for the 
purposes of the study, as there is no universal agreement on the criteria for 
dipstick diagnosis of relapsed Nephrotic Syndrome. 
 
Informed consent was obtained from the legal guardians of patients included in the 
study and assent was obtained from children old enough to understand the study 
(Appendix A). 
 
Permission to conduct the study at CMJAH was obtained from the Chief Executive 
Officer (CEO) of the hospital. Ethics approval to undertake the study was granted 
by Human Research Ethics Committee (HREC), University of Witwatersrand 
(M130227) (Appendix B). 
 
Funding: The vitamin D Kits were purchased using existing funds belonging to the 
Division of Paediatric Nephrology at CMJAH. 
 
 
2.5 Statistical Analysis 
Study data was collected and managed using Microsoft Excel and IBM SPSS 
Statistics, Version 22, hosted by University of the Witwatersrand.  
Descriptive statistical analysis was performed by the primary investigator, and 
checked by a senior colleague experienced in this field. 
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Relationships between continuous variables were expressed as scatter plots, and 
theoretically expressed by Pearson’s correlation. Independent sample t tests were 
used to compare intergroup differences in the mean level of vitamin D when there 
were two variables. The one-way ANOVA was used to compare data in cases 
where there were more than two variables.  
 
A p-value of <0.05 was considered to be statistically significant. 
 
 
2.6 Limitations 
i) The vitamin D status of the background population was unknown. 
ii) The number of participants in our study was short of the minimum    
    requirement of 100. 
iii) In the group on dialysis, only patients with Nephrotic syndrome on      
    dialysis were included, hence the numbers were much smaller than other  
    studies looking at children on dialysis. 
iv) The study included patients on vitamin D replacement. 
v) The diagnosis of Nephrotic Syndrome was arbitrary. 
vi) The patients’ vitamin D status was not always assessed at the time the  
     patients had Nephrotic Syndrome with relapse. 
vii) The intake of natural vitamin D sources was not documented 
viii) Patients with malabsorption and liver disease were not specifically     
excluded from the study although there were no patients in the sample who 
had a diagnosis of these two conditions. 
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3.0 RESULTS 
3.1 Patient Characteristics 
The characteristics of patients in terms of their age, sex, race, BMI Z Score; if they 
were receiving peritoneal dialysis; the season blood samples were taken; whether 
they were paying for medical services as a marker of socioeconomic status; their 
CKD staging; duration of illness and whether they were receiving vitamin D 
supplementation or not is shown in Table 1 below. 
 
Table 1-Characteristics of patients  
Variable  Value 
Patients (n) 69 
Age (years) 10.7 ± 4.2* 
Sex n (%) 
Male 
Female 
 
31 (45) 
38 (55) 
Race n (%) 
Black 
Asian 
Coloured 
White 
 
56 (81) 
3 (5) 
5 (7) 
5 (7) 
Peritoneal Dialysis n (%) 
Yes 
No 
 
12 (17) 
57 (83) 
Season of samples n 
Winter/Spring 
Summer/Autumn 
 
50  
19  
Paid for medical services n (%) 
Yes 
No 
 
30 (43) 
39 (57) 
CKD Staging n (%) 
1 
2 
3 
4 
5 
 
33 (48) 
11 (16) 
8 (12) 
8 (12) 
9 (13) 
Duration of Illness (months) 69 ± 59* 
Vitamin D supplementation n (%) 21 (30) 
BMI Z Score -0.09 ± 0.08* 
* Mean ± SD 
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A total of 74 patients met the inclusion criteria and were initially included in the 
study. Of these, four subjects were excluded due to technical factors that 
prevented accurate 25OHD levels from being obtained from their samples. One 
subject was excluded because a blood sample for 25OHD was not taken. 
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3.2 25OHD trend in our patient population 
 
 
 
 
 
Figure 1: Histogram – Vitamin D levels for the entire sample of patients 
 
 
The trend of 25OHD levels in the sample of patients, as depicted by the histogram 
above, indicates that there was a skewed distribution of vitamin D levels to the left. 
The overall median 25OHD concentration was 74 nmol/L (IQR 44-95 nmol/L). Six 
(9%) patients were vitamin D deficient, 14 (20%) insufficient and the remaining 49 
(71%) replete.  
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There were 21 (30%) patients on vitamin D supplementation. When these patients 
were excluded from the analysis, the median vitamin D level decreased to 63 
nmol/L (IQR 44-93 nmol/L). This level is still within normal limits. Patients on 
supplementation were not excluded from all analyses. 
 
As noted, there are two peaks in the histogram. The first peak represents patients 
who are vitamin D insufficient, and the second peak those who are have sufficient 
vitamin D levels. 
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3.3 25OHD and Age 
 
 
 
Figure 2: Scatter plot - 25OHD vs age 
 
There was no significant correlation between 25OHD and age (r= -0.07, p=0.90). 
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3.4 25OHD and Sex 
 
Table 2: Comparing mean 25OHD levels between males and females 
  
 
Sex N Mean 
Std. 
Deviation 
p value 95% 
Confidence 
Interval of 
Mean 
Difference 
25OHD Male 40 79.05 34.53 0.22 -3.2; 34.0 
Female 29 67.86 39.50   
 
 
There was no significant difference between mean 25OHD levels and the sexes 
(p=0.22).  
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3.5 25OHD and Race 
Figure 3 shows the mean 25OHD levels in the different ethnic groups. 
 
 
 
 
 
Figure 3: Box and Whisker Plot-25OHD vs Race 
 
The majority of the patients in our cohort were black. The greater variation in 
vitamin D levels in the black race group when compared to the other race groups 
is most likely explained by the fact that there were more patients in the black group 
than in the other race groups. There was also a trend that the 25OHD levels in the 
black race group were lower compared to the other races. White patients had the 
highest 25OHD levels. Overall there was no significant difference in 25OHD levels 
between ethnic groups (p=0. 360). 
Legend 
A: Asian 
B: Black 
C: Coloured 
W: White 
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3.6 25OHD and Financial status 
 
Table 3: Comparing financial status with mean 25OHD levels 
  
 
Financial 
Category N Mean 
Std. 
Deviation 
p value 95% 
Confidence 
Interval of 
Mean 
Difference 
25OHD Non Paying 39 73.97 35.14 0.92 -18.8; 17.1 
Paying 30 74.83 39.55   
 
 
There was no significant difference between mean 25OHD levels and financial 
status (p=0.92). 
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3.7 25OHD and Season 
 
 
 
 
 
Figure 4: Box and Whisker Plot-25OHD vs. Season 
 
Mean 25OHD levels tended to be lower in winter and spring compared to summer 
and autumn although this was not statistically significant (p=0.14). There was 
more variation in winter, which could be attributed to many more blood samples 
taken during this period.  
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3.8 25 OHD and BMI 
 
 
 
 
Figure 5: Scatter plot – 25OHD vs. BMI Z Score 
 
There was no correlation between 25OHD and BMI Z Score (r= -0.15, p=0.22). 
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3.9 25OHD and GFR 
 
 
 
 
Figure 6: Scatter Plot-25OHD vs. eGFR 
 
 
Although there was a trend that patients with worse renal function had higher 
levels of 25OHD, this was not found to be statistically significant (r= -0.23, p=0.06).  
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3.10 25OHD and Duration of Illness 
 
 
 
 
Figure 7: Scatter plot-25OHD vs Duration of Illness 
 
 
There was no relationship between duration of illness and 25OHD (r= -0.02, 
p=0.09).  
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3.11 25OHD and Peritoneal Dialysis 
 
Table 4: Comparing mean 25OHD levels between patients on Peritoneal Dialysis 
and those who aren’t on dialysis 
  
 
Peritoneal 
Dialysis N Mean 
Std. 
Deviation 
p value 95% 
Confidence 
Interval of 
Mean 
Difference 
25OHD Yes 12 66.92 37.93 0.45 -32.4; 14.4 
 No 57 75.91 36.76   
 
 
There were 12 (17.4%) patients on dialysis and although mean 25OHD levels in 
this group were marginally lower than those who weren’t on dialysis (p=0.45) this 
was not statistically significant.  
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3.12 25OHD and Albumin 
 
 
 
 
 
Figure 8- Scatter plot: 25OHD vs. Serum Albumin 
 
Serum 25OHD levels showed a significantly positive correlation with serum 
albumin (r=0.48, p=o.oo).  
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3.13 25OHD and Nephrotic Syndrome Relapse vs. Remission 
 
Table 5 – Comparing mean 25OHD levels in patients with Nephrotic Syndrome 
with relapse vs. remission 
  
 
Nephrotic 
Syndrome N Mean 
Std. 
Deviation 
 
 p value 
95% 
Confidence 
Interval of 
Mean 
Difference 
25OHD Relapse 19 49.90 32.40 .000 -50.0; -13.0 
Remission 50 83.64 34.32   
 
There was a significant difference in mean 25OHD levels between the children 
who had been defined as having Nephrotic Syndrome with relapse and those who 
were in remission. Mean 25OHD levels in patients who had Nephrotic Syndrome 
with relapse were insufficient, and those in remission were replete. 
 
3.14 Serum Albumin and Nephrotic Syndrome with Relapse 
 
Table 6 – Comparing mean Serum Albumin levels in patients with Nephrotic 
Syndrome with relapse vs. remission: 
  
 
 Nephrotic 
Syndrome N Mean 
Std. 
Deviation 
 
p value 
95% 
Confidence 
Interval of 
Mean 
Difference 
Albumin Relapse 19 31.80 10.14 .000 -12.0; -4.2 
Remission 50 39.87 5.80   
 
There was a significant difference in mean serum albumin levels in patients with 
Nephrotic Syndrome with relapse compared to those in remission. Mean serum 
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albumin levels in patients who had relapsed were lower and those in remission 
were normal giving us confidence that our definition of Nephrotic Syndrome with 
relapse was correct for the study. 
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4.0 DISCUSSION 
 
There is limited data available regarding the vitamin D status of children in South 
Africa, and even less so in chronically ill children. Vitamin D sufficiency, defined as 
>50nmol/l, was found in 71% of patients in our study population. Similar results 
were found in a study of healthy 10-year-old urban children living in Johannesburg, 
where 74% were vitamin D sufficient16.  
 
A study in Brazil demonstrated that vitamin D deficiency was rare in a sample of 
chronic kidney disease patients inhabiting a subtropical region of Brazil, where 
ultraviolet radiation is elevated throughout the year20. Only 0.6% were vitamin D 
deficient, however, 39.6% of patients in the study had vitamin D insufficiency20. 
Vitamin D deficiency was rare in our study with only 9% of patients with levels 
<30nmol/l. It is important to note however that different values were used to define 
vitamin D insufficiency in the study in Brazil, which had a higher threshold of 
labeling patients as vitamin D insufficient. This may have accounted for the larger 
numbers of vitamin D insufficiency seen in that group. 
 
An Asian study found 25OHD insufficiency and deficiency was more common in 
children with CKD and was indirectly related to the level of kidney function21. Our 
study found no significant relationship between 25OHD and level of renal 
dysfunction. The Asian study had a large sample, namely 2895 CKD patients, 
compared to our 70 patients, which may account for differing results. 
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In two separate studies done previously, there was an overall negative correlation 
of 25OHD levels with age6, 7. This is a contrast to our study, where there was no 
relationship between 25OHD levels and age. However, both these studies only 
looked at children with Nephrotic Syndrome, whereas we looked at all children 
attending the Paediatric Renal Outpatient Clinic. The age range of patients in one 
study was between 2 and 15 years of age6. The author attributed their findings to 
the increasing demand of a growing skeleton to achieve peak bone mass6. The 
age range of children in our study was much wider and perhaps factors other than 
the increasing demand of a growing skeleton may play a role. 
 
In an Argentinian study, low 25OHD levels were more frequently seen in female 
patients and in patients with an increased BMI22. Similar results were found in a 
study done in Saudi Arabia, where there was a significant inverse relationship 
between circulating vitamin D levels and fat mass23. This could partly be explained 
by the fact that females have more fat as a percentage body mass, which results 
in reduced vitamin D bioavailability24. Mean 25OHD levels were lower in female 
compared to male children in our sample, although the results were not statistically 
significant. There was also a trend in our population that children with larger BMI Z 
scores tended to have lower 25OHD levels (r= -0.15). However, once again, the 
results were not statistically significant (p=0.22).  
 
There wasn’t any difference found between 25OHD levels and families who had to 
pay a fee and those who did not, as a marker of the relationship between vitamin 
D status and socioeconomic status. A study conducted in Delhi, India, found a 
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third of the children to be vitamin D deficient, with the majority of the children in the 
study coming from low socioeconomic backgrounds. These findings may have 
been attributed to the fact that dietary calcium intake was significantly lower in the 
low socioeconomic group as other parameters such as sunlight was the same 
between the groups. 25 The findings in our study may have differed because of the 
small sample size. In addition, our marker of socioeconomic status, whether 
patients paid a fee on not, may not have been entirely reflective for economic 
status, as they may have been exempted from paying a fee for another reason. 
 
It is important to note that some studies looking at the relationship between BMI Z 
Scores and socioeconomic status with vitamin D status were done in healthy 
children and may not be a meaningful comparison to our study. Further studies are 
needed to investigate these risk factors for low 25OHD levels in children with CKD. 
 
In patients with Nephrotic Syndrome, vitamin D binding protein, which has a 
molecular weight of less than that of albumin, is lost in the urine together with 
25OHD6. In keeping with this finding, 25OHD and albumin levels were found to be 
significantly lower in patients with Nephrotic Syndrome with relapse compared to 
those in remission in our sample. In the 19 (27.5%) children in our subgroup who 
had Nephrotic Syndrome with relapse the mean 25OHD levels 49.9 +/- 
32.4nmol/L, which was borderline insufficient.  
 
In a previous study looking at the vitamin D status in patients on chronic dialysis, 
there was a high prevalence of deficiency and insufficiency in children on chronic 
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dialysis26. In our study there was a trend for patients on peritoneal dialysis to have 
lower 25OHD levels, although these results were not statistically significant.  
There were very few patients in our study who were on dialysis (12 subjects) and 
that may contribute to the results not being statistically significant. Another factor 
that may contribute to differing results26 is that the 25OHD levels in the published 
study were taken during winter, which may have accounted for their results being 
lower. 
 
 
This study has a number of limitations. There was no control group of normal 
individuals and there were fewer subjects than that of the calculated sample size 
required. In the group on dialysis, only patients with Nephrotic syndrome on 
dialysis were included, hence the numbers were much smaller than other studies 
looking at children on dialysis. 
 
 
5.0 CONCLUSION 
 
In conclusion, in contrast to other studies on this topic, it would appear from our 
results that the majority of children with renal disease in Johannesburg, South 
Africa are vitamin D sufficient. This is reassuring as it implies that there is no need 
for routine vitamin D supplementation in this sample of children. However, at risk 
patients (dark-skinned or Nephrotic syndrome with relapse) may still need to be 
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screened for vitamin D deficiency and insufficiency and supplemented if 
necessary. 
 
Just less than a third of patients in our cohort were receiving vitamin D 
supplementation. When this group was excluded from the analysis the mean 
25OHD levels were still sufficient.  
 
Mean albumin levels were significantly lower in children with Nephrotic Syndrome 
who had relapsed compared to children who were in remission confirming that our 
definition of Nephrotic Syndrome with relapse accurately reflected the clinical 
picture. There was a significant difference in 25OHD levels in children with 
Nephrotic Syndrome with relapse compared to those in remission in keeping with 
previous studies as mentioned above. 
 
Our recommendations would be to do future studies with a larger number of 
patients especially those with Nephrotic Syndrome in relapse and in those on 
dialysis.  
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7.0 APPENDICES 
Appendix A: Consent/Assent Form Dear	  Patient,	  Parent/Guardian	  	  Good	  day,	  	  My	  name	  is	  Dr.	  Sharika	  Raga	  and	  I	  am	  currently	  studying	  to	  become	  a	  paediatrician.	  As	  part	  of	  my	  training,	  I	  need	  to	  do	  a	  research	  project.	  I	  will	  be	  doing	  a	  study	  about	  vitamin	  D	  levels	  in	  children	  who	  stay	  in	  hospital	  for	  a	  long	  time	  and	  children	  who	  have	  kidney	  disease.	  You	  are	  welcome	  to	  be	  a	  part	  of	  it.	  	  Vitamin	  D	  is	  important	  in	  the	  human	  body,	  especially	  with	  the	  growth	  of	  bones.	  Sunlight	  helps	  Vitamin	  D	  to	  work.	  The	  kidneys	  also	  help	  make	  vitamin	  D.	  	  When	  you	  are	  admitted	  to	  hospital,	  especially	  for	  a	  long	  time,	  you	  may	  not	  get	  enough	  sunlight.	  This	  may	  make	  it	  difficult	  for	  the	  vitamin	  D	  to	  work	  properly.	  	  We	  are	  doing	  a	  study	  to	  see	  if	  vitamin	  D	  levels	  are	  less	  when	  you	  stay	  in	  hospital	  or	  if	  you	  have	  kidney	  disease	  and	  visit	  our	  clinic.	  	  In	  order	  for	  us	  to	  measure	  vitamin	  D,	  we	  have	  to	  take	  some	  blood	  from	  you.	  When	  we	  take	  blood	  for	  your	  routine	  blood	  tests	  (when	  you	  are	  admitted	  or	  when	  you	  visit	  our	  clinic)	  we	  will	  take	  an	  extra	  tube	  of	  blood	  (2ml).	  If	  you	  stay	  in	  hospital	  for	  4	  weeks	  or	  longer,	  we	  will	  take	  some	  more	  blood	  before	  you	  go	  home.	  This	  blood	  sample	  will	  be	  taken	  along	  with	  your	  routine	  blood	  tests.	  There	  will	  no	  extra	  needle	  sticks	  as	  we	  will	  only	  take	  the	  extra	  blood	  if	  we	  were	  going	  to	  do	  a	  blood	  test	  anyway.	  	  If	  you	  do	  not	  want	  us	  to	  take	  the	  extra	  blood	  tube,	  or	  if	  you	  agree	  and	  then	  change	  your	  mind,	  we	  will	  still	  provide	  the	  same	  treatment	  to	  you.	  	  	  All	  the	  results	  we	  get	  from	  the	  extra	  test	  will	  be	  kept	  strictly	  confidential	  and	  you	  will	  not	  be	  identified	  in	  the	  study.	  	  If	  there	  are	  any	  problems	  with	  the	  blood	  results	  we	  will	  let	  you	  know	  and	  your	  doctors	  will	  treat	  you	  accordingly.	  	  We	  are	  hoping	  that	  this	  study	  will	  help	  us	  help	  you	  and	  other	  children	  too.	  	  	  Thank	  you	  for	  taking	  the	  time	  to	  consider	  our	  request.	  If	  you	  are	  willing	  to	  be	  a	  part	  of	  this	  study,	  please	  could	  you	  kindly	  sign	  below.	  	  	  Dr	  S	  Raga	  and	  Dr	  CS	  Levy	  Contact	  Number:	  072	  934	  3040	  	  Patient	  Name___________________________________________________________________________	  	  Signature_______________________________________	   Date_____________	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Appendix B: Ethics Clearance Certificate 
 
 
